Showing results (1-10 of 83) with videos related to
Sort By:
Pageof 9
Clinical Breast Cancer|December 1, 2010
Does the PI3K pathway play a role in basal breast cancer?Stacy L MoulderFuture Oncology (London, England)|June 4, 2008
Ixabepilone for the treatment of taxane-refractory breast cancerStacy L MoulderClinical Breast Cancer|September 1, 2010
Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trialsStacy L MoulderThe Oncologist|June 1, 2017
Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the FieldClinton Yam, Sendurai A Mani, Stacy L MoulderSeminars in Oncology|July 26, 2002
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancerCarlos L Arteaga, Stacy L Moulder, F Michael YakesCancer Journal (Sudbury, Mass.)|July 11, 2007
Adjuvant biologic therapy for breast cancerBarbara S Craft, Gabriel N Hortobagyi, Stacy L MoulderAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Innovative Strategies: Targeting Subtypes in Metastatic Breast CancerMark D Pegram, Yu Zong, Clinton Yam, et al.BMC Cancer|May 30, 2015
Multiple gene aberrations and breast cancer: lessons from super-respondersJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.Oncoscience|August 6, 2015
Challenges and perspective of drug repurposing strategies in early phase clinical trialsShumei Kato, Stacy L Moulder, Naoto T Ueno, et al.NPJ Precision Oncology|September 9, 2022
Impact of TP53 mutations in Triple Negative Breast CancerZahi I Mitri, Nour Abuhadra, Shaun M Goodyear, et al.Pageof 9